The change is aimed to prepare the Foundation to major challenges coming in the near future, including a significant increase in the number of projects and funds, the participation of the Foundation in EU grants and the incorporation of high throughput omics technology in most observational studies and projects.
We are most grateful to Dr. Josep Maria Torner, who worked hardly during the past three years, contributing to the consolidation and expansion of the Foundation. His experience in the pharmaceutical industry and his easy interaction with the main leaders in the field of cirrhosis and intensive care units have been of great importance in this success. He has also been crucial in the successful development of the PREDICT study and in the design of the future Latin-American ACLF ACLARA Study. We all are convinced that with his past experience and the expertise gained in the Foundation, Josep Maria will get further professional achievements and gratifications in a near future.